Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59‐7939, an oral, direct factor Xa inhibitor

By D. Kubitza, M. Becka, B. Voith, M. Zuehlsdorf, G. Wensing. Clinical pharmacology and therapy, 2005

675 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Critical Care and Intensive Care Medicine, Hematology

View Paper: https://www.semanticscholar.org/paper/d3cbaa7d95001605026fdec7cdd71a201ef63ecb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. J. Halperin
2. Robert M. Califf

Citations in the corpus

• Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. (2011, background): “While rivaroxaban is predominantly metabolized by the liver, approximately one-third is cleared renally.(24) In patients with moderate renal insufficiency (CrCl 30–49 mL/min), there is a moderate but relevant effect on rivaroxaban exposure; maximal serum concentrations are 25–30% higher(14) and phar”